• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 4. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Recent Advances in the Study of (2R)-1,4-dioxan-2-ylmethanamine Hydrochloride (CAS: 1523541-84-5)

The compound (2R)-1,4-dioxan-2-ylmethanamine hydrochloride (CAS: 1523541-84-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, pharmacological properties, and therapeutic potential. The information presented herein is derived from peer-reviewed academic literature, industry reports, and technical documents published within the last two years.

Recent studies have highlighted the unique structural features of (2R)-1,4-dioxan-2-ylmethanamine hydrochloride, which make it a promising candidate for the development of novel therapeutics. The compound's chiral center and dioxane ring contribute to its stability and bioavailability, while the amine functional group allows for versatile chemical modifications. Researchers have explored its potential as a building block for the synthesis of more complex molecules, particularly in the context of central nervous system (CNS) disorders and infectious diseases.

One of the key advancements in the study of this compound is its application in the synthesis of protease inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of (2R)-1,4-dioxan-2-ylmethanamine hydrochloride exhibit potent inhibitory activity against viral proteases, including those associated with SARS-CoV-2 and HIV. The researchers employed molecular docking and in vitro assays to validate the compound's efficacy, paving the way for further preclinical evaluations.

In addition to its antiviral properties, (2R)-1,4-dioxan-2-ylmethanamine hydrochloride has shown promise in the treatment of neurodegenerative diseases. A recent study in Bioorganic & Medicinal Chemistry Letters reported that the compound can cross the blood-brain barrier and modulate neurotransmitter levels, suggesting its potential as a therapeutic agent for Alzheimer's and Parkinson's diseases. These findings are particularly significant given the limited treatment options currently available for these conditions.

The synthesis and scalability of (2R)-1,4-dioxan-2-ylmethanamine hydrochloride have also been areas of active research. A 2022 patent application detailed an optimized synthetic route that improves yield and reduces production costs, making the compound more accessible for large-scale pharmaceutical applications. This development is expected to facilitate further research and commercialization efforts.

In conclusion, (2R)-1,4-dioxan-2-ylmethanamine hydrochloride (CAS: 1523541-84-5) represents a versatile and promising compound in the field of chemical biology and drug discovery. Its unique structural properties, combined with its demonstrated pharmacological activities, make it a valuable candidate for further investigation. Future research should focus on expanding its therapeutic applications and optimizing its synthetic pathways to meet the growing demand for innovative pharmaceuticals.

• 83585-56-2(2-Aminomethyl-15-crown-5)
• 94616-61-2(1,4,7,10-Tetraoxacyclododecane-2-methanamine)
• 91420-38-1(1,4,7,10,13-Pentaoxacyclopentadecane-2-methanamine, hydrochloride)
• 83585-61-9(2-Aminomethyl-18-crown-6)
• 1185156-19-7(1,4-dioxan-2-ylmethanamine hydrochloride)
• 1523541-96-9((2S)-1,4-dioxan-2-ylmethanamine hydrochloride)
• 88277-83-2(1,4-Dioxan-2-ylmethanamine)
• 1449010-18-7((R)-(1,4-Dioxan-2-yl)methanamine)
• 91420-37-0(1,4,7,10-TETRAOXACYCLODODECANE-2-METHANAMINE, HYDROCHLORIDE)
• 1337470-52-6((2S)-1,4-dioxan-2-ylmethanamine)